Anika Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sidoti Downgrades Anika Therapeutics (ANIK) to Neutral
February 22, 2019 8:48 AM ESTSidoti analyst James Sidoti downgraded Anika Therapeutics (NASDAQ: ANIK) from Buy to Neutral with a price target of $41.00 (from $56.00).
The analyst cited uncertainty regarding CINGAL approval.
For an analyst ratings summary and ratings history on Anika Therapeutics... More
Anika Therapeutics (ANIK) Tops Q4 EPS by 21c
February 21, 2019 4:20 PM ESTAnika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.54, $0.21 better than the analyst estimate of $0.33. Revenue for the quarter came in at $27 million versus the consensus estimate of $26.17 million.
Anika continued to deliver strong earnings and cash flow in the fourth quarter, entering 2019 well-positioned to... More
